Life Science Tools & Diagnostics What We Learned From a Drug Discovery Expert About AI’s Impact on Life Science Tools

Research evidence excerpt

Life Science Tools & Diagnostics What We Learned From a Drug Discovery Expert About AI’s Impact on Life Science Tools

J P M O R G A N North America Equity Research

27 May 2026

Life Science Tools & Diagnostics

What We Learned From a Drug Discovery Expert About

AI’s Impact on Life Science Tools

We spoke with the founder of a life sciences advisory firm supporting pharma and Life Science Tools & Diagnostics

ACbiotech companies, as well as investors, to gain a better understanding of AI’s impact Casey Woodring

on drug discovery and the implications for life science tools. Following our (1-212) 622-9074

conversation, it is our view that AI-driven compression of target ID/hypothesis casey.woodring@jpmchase.com

generation timelines could increase subsequent wet lab validation volume, benefiting Sebastian Sandler

high-throughput instruments and multi-omics tool providers, while potentially (1-212) 622-8464

pressuring lower-throughput/animal-model-adjacent tools. Structural biology sebastian.sandler@jpmchase.com

platforms (e.g., NMR, cryo-EM, X-ray crystallography) and bioanalytical platforms Marta Nazarovets Zaremba

such as mass spectrometry may also benefit as AI raises the bar for data quality. This (1-212) 622-6046

marta.zaremba@jpmchase.com

shift could drive demand toward higher-end systems and accelerate an upgrade cycle

Jaden Rismayaway from lower-end benchtop instruments, as these platforms evolve from

(1-212) 622-8479

exploratory tools into data quality gatekeepers. Offsetting this, in silico compound jaden.rismay@jpmchase.com

screening could reduce demand for traditional screening instrumentation/reagents, J.P. Morgan Securities LLC

and miniaturization/automation could modestly reduce reagent consumption despite

higher throughput.